Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02848248 · ClinicalTrials.gov registry record · Phase 1
A Safety Study of SGN-CD123A in Patients With Acute Myeloid Leukemia
A Phase 1 study, sponsored by Seagen.
- Terminated
- Registry status
- Phase 1
- Development phase
- 17
- Enrollment target
NCT02848248 is a Phase 1 study that was terminated before completion, run by Seagen. The registered enrollment target is 17 participants.
The verdict
NCT02848248, a Phase 1 study, was terminated before completion, sponsored by Seagen.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 17 participants
- Enrollment target
Study Summary
The study will examine the safety profile of SGN-CD123A. The study will test increasing doses of SGN-CD123A given every 3 weeks to patients.
Interventions
- DRUG SGN-CD123A
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2016-08 |
| Est. Completion | 2018-04-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02848248
The ClinicalTrials.gov registry entry for NCT02848248 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Seagen, which has 84 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which SGN-CD123A is the first listed.
NCT02848248 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02848248 about?
NCT02848248 is a clinical study titled "A Safety Study of SGN-CD123A in Patients With Acute Myeloid Leukemia". The study will examine the safety profile of SGN-CD123A. The study will test increasing doses of SGN-CD123A given every 3 weeks to patients.
What is the current status of trial NCT02848248?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 17 participants. The study started on 2016-08. Estimated completion is 2018-04-06.
What interventions are being tested in trial NCT02848248?
The interventions under investigation include: SGN-CD123A (DRUG).
Who is sponsoring clinical trial NCT02848248?
This trial is sponsored by Seagen, which has 84 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.